Real-time Vasoactive Inotrope Score to Predict Poor Outcome in Pediatric Patients



Ealla Atari, MD^{1,2}, Christopher Page-Goertz, MD^{1,3}, Neil McNinch MS, RN⁴, Ryan Nofziger, MD, MBA^{1,3}

DATA

1. Akron Children's Hospital Department of Pediatrics, 2. Akron Children's Hospital Department of Medical Education, 3. Akron Children's Hospital Division of Critical Care Medicine, 4. Rebecca D. Considine Research Institute

BACKGROUND

- The vasoactive-inotrope-score (VIS) has been used to objectively quantify the degree of cardiovascular support in critically ill children
- Previous studies have measured VIS at predetermined time points
- Static measures may not reflect totality of support in ICU stay
- Purpose of our study was to calculate a cumulative VIS in patients admitted to a pediatric ICU to determine if cumulative VIS predicts a complicated ICU course
- Hypothesis: higher cumulative VIS will predict poor outcome in this population

METHODS

- Single center retrospective study of all patients admitted to PICU between 2019-2021 that received vasoactive agents
- Cumulative VIS was calculated using a predetermined algorithm generated from real-time infusion pump data
- Sensitivity a nalysis was used to determine the most optimal cut-off utilizing Youden's statistic
- Poor outcome was defined a priori as cardiac arrest, ECMO requirement, or mortality



10,000 × Vasopressin dose (U/kg/min) + 100 × Epinephrine dose (µg/kg/min) + 100 × Norepinephrine dose (µg/kg/min) + 50 × Levosimendan dose (µg/kg/min) + 25 × Olprinone dose (µg/kg/min) + 20 × Methylene blue dose (mg/kg/h) + 10 × Milrinone dose (µg/kg/min) + 10 × Phenylephrine dose (µg/kg/min) + 0.25 × Angiotensin II dose (ng/kg/min) + Dobutamine dose (µg/kg/min) + Dopamine dose (µg/kg/min) + Enoximone dose (µg/kg/min)

Figure 1. Vasoactive-inotrope score equation

With Poor Outcome Without Poor Outcome Median [IQR] Median [IQR] p-value AgeMonths 50 [3, 152] 61 [13, 162.5] 0.038 Noregi 1.3 [0, 4.6] 0 [0, 0] 0.001 Epi 2.3 [0.2, 5.9] 0 [0, 0] 0.001 Milrinone 0 [0, 2.4] 0 [0, 0] 0.001 Dopa 0 [0, 0] 0 [0, 0] 0.001 Phenyl 0 [0, 0] 0 [0, 0] 0.001 Vaso 0 [0, 7.5] 0 [0, 0] 0.001 TotVIS12 141.6 [32.5, 287.1] 0 [0, 0] 0.001 TotVIS18 201.3 [56.9, 704.6] 0 [0, 0] 0.001 TotVIS18 335.5 [79.9, 990.3] 0 [0, 0] 0.001 TotVIS18 335.5 [79.9, 990.3] 0 [0, 0] 0.001 AveVIS12 11.8 [2.7, 23.9] 0 [0, 0] 0.001 AveVIS12 11.8 [2.7, 23.9] 0 [0, 0] 0.001 AveVIS18 51.2 [2.7, 7.1] 0 [0, 0] 0.001 AveVIS36 9.3 [2.7, 27.5] 0 [0, 0]	stratified by	poor outcome status		
Median [IQR] Median [IQR] p-value AgeMonths 50 [3, 152] 61 [13, 162.5] 0.038 Norspi 1.3 [0, 4.6] 0 [0, 0] <0.001 Epi 2.3 [0.2, 5.9] 0 [0, 0] <0.001 Milrinone 0 [0, 0] 0 [0, 0] <0.001 Dopa 0 [0, 0] 0 [0, 0] <0.001 Phenyl 0 [0, 0] 0 [0, 0] <0.001 Vaso 0 [0, 7.5] 0 [0, 0] <0.001 TotVIS1 2013 [56.2, 980.3] 0 [0, 0] <0.001 TotVIS24 206.3 [66.2, 990.3] 0 [0, 0] <0.001 TotVIS48 335.6 [97.9, 990.3] 0 [0, 0] <0.001 TotVIS48 10.7 [2.2, 27.1] 0 [0, 0] <0.001 AveVIS4 1.12 [3.2, 39.1] 0 [0, 0] <0.001 AveVIS4 9.3 [2.7, 27.5] 0 [0, 0] <0.001 AveVIS4 9.4 [2.8, 41.3] 0 [0, 0] <0.001 AveVIS4 9.3 [2.7, 27.5] 0 [0, 0] <0.001 AveVIS48 7.4 [2.2,		With Poor Outcome	Without Poor Outcome	
Age Months 50 [3, 152] 61 [13, 162.5] 0.038 Norepi 1.3 [0, 4.6] 0 [0, 0] <0.001 Epi 2.3 [0, 2, 5.9] 0 [0, 0] <0.001 Milrinone 0 [0, 2, 4] 0 [0, 0] <0.001 Dopa 0 [0, 0] 0 [0, 0] <0.001 Vaso 0 [0, 7.5] 0 [0, 0] <0.001 TotVIS6 64.3 [13.1, 162.5] 0 [0, 0] <0.001 TotVIS12 141.6 [32.5, 287.1] 0 [0, 0] <0.001 TotVIS12 206.3 [66.2, 990.3] 0 [0, 0] <0.001 TotVIS4 355.3 [105.2, 990.3] 0 [0, 0] <0.001 TotVIS4 355.3 [105.2, 990.3] 0 [0, 0] <0.001 AveVIS5 10.7 [2.2, 27.1] 0 [0, 0] <0.001 AveVIS4 8.6 [2.8, 41.3] 0 [0, 0] <0.001 AveVIS5 10.7 [2.2, 27.5] 0 [0, 0] <0.001 AveVIS4 8.6 [2.8, 41.3] 0 [0, 0] <0.001 AveVIS5 9.3 [2.7, 27.5] 0 [0, 0] <0.001		Median [IQR]	Median [IQR]	p-value
Norspi 1.3 [0, 4.6] 0 [0, 0] < 0.001	AgeMonths	50 [3, 152]	61 [13, 162.5]	0.038
Epi 2.3 [0.2, 5.9] 0 [0, 0] < 0.001	Norepi	1.3 [0, 4.6]	0 [0, 0]	< 0.001
Milrinone 0 [0, 2.4] 0 [0, 0] < 0.001	Epi	2.3 [0.2, 5.9]	0 [0, 0]	< 0.001
Dopa 0 [0, 0] 0 [0, 0] < 0.001	Milrinone	0 [0, 2.4]	0 [0, 0]	< 0.001
Phenyl 0 [0, 0] 0 [0, 0] < 0.001	Dopa	0 [0, 0]	0 [0, 0]	< 0.001
Vaso 0 [0, 7.5] 0 [0, 0] < 0.001	Phenyl	0 [0, 0]	0 [0, 0]	< 0.001
TotVIS6 64.3 [13.1, 162.5] 0 [0, 0] < 0.001	Vaso	0 [0, 7.5]	0 [0, 0]	< 0.001
TotVIS12 141.6 [32.5, 287.1] 0 [0, 0] < 0.001	TotVIS6	64.3 [13.1, 162.5]	0 [0, 0]	< 0.001
TotVIS18 201.3 [56.9, 704.6] 0 [0, 0] < 0.001	TotVIS12	141.6 [32.5, 287.1]	0 [0, 0]	< 0.001
TotVIS24 206.3 [66.2, 990.3] 0 [0, 0] < 0.001	TotVIS18	201.3 [56.9, 704.6]	0 [0, 0]	< 0.001
TotVIS36 335.6 [97.9, 990.3] 0 [0, 0] < 0.001	TotVIS24	206.3 [66.2, 990.3]	0 [0, 0]	< 0.001
TotVIS48 355.3 [105.2, 990.3] 0 [0, 0] < 0.001	TotVIS36	335.6 [97.9, 990.3]	0 [0, 0]	< 0.001
AveVIS6 10.7 [2.2, 27.1] 0 [0, 0] < 0.001	TotVIS48	355.3 [105.2, 990.3]	0 [0, 0]	< 0.001
AveVIS12 11.8 [2.7, 23.9] 0 [0, 0] < 0.001	AveVIS6	10.7 [2.2, 27.1]	0 [0, 0]	< 0.001
AveVIS18 11.2 [3.2, 39.1] 0 [0, 0] < 0.001	AveVIS12	11.8 [2.7, 23.9]	0 [0, 0]	< 0.001
AveVIS24 8.6 [2.8, 41.3] 0 [0, 0] < 0.001	AveVIS18	11.2 [3.2, 39.1]	0 [0, 0]	< 0.001
AveVIS36 9.3 [2.7, 27.5] 0 [0, 0] < 0.001	AveVIS24	8.6 [2.8, 41.3]	0 [0, 0]	< 0.001
AveVIS48 7.4 [2.2, 20.6] 0 [0, 0] <0.001	AveVIS36	9.3 [2.7, 27.5]	0 [0, 0]	< 0.001
CumVIS 806.5 [174.8, 2429.9] 0 [0, 0] < 0.001	AveVIS48	7.4 [2.2, 20.6]	0 [0, 0]	<0.001
POPCdiff 4 [2, 5] 0 [0, 0] < 0.001	CumVIS	806.5 [174.8, 2429.9]	0 [0, 0]	< 0.001
PCPCdiff 5 [2, 5] 0 [0, 0] < 0.001	POPCdiff	4 [2, 5]	0 [0, 0]	< 0.001
PIM2 -1.9 [-3.3, -0.1] -4.9 [-6.3, -4.5] < 0.001	PCPCdiff	5 [2, 5]	0 [0, 0]	< 0.001
PIM3 -2.4 [-3.5, -0.1] -5.5 [-6.1, -4.8] < 0.001	PIM2	-1.9 [-3.3, -0.1]	-4.9 [-6.3, -4.5]	< 0.001
PRISM3 23 [12, 30] 2 [0, 5] < 0.001	PIM3	-2.4 [-3.5, -0.1]	-5.5 [-6.1, -4.8]	< 0.001
PELOD 32 [21, 42] 1 [0, 10] < 0.001	PRISM3	23 [12, 30]	2 [0, 5]	< 0.001
LOShours 98 [34, 294] 28 [18, 56] < 0.001	PELOD	32 [21, 42]	1 [0, 10]	< 0.001
	LOShours	98 [34, 294]	28 [18, 56]	< 0.001

Table 2. Results of univariate logistic regression with ROC curve analysis

Poor Outcome:	AUC	CI	SE	p-value
AgeMonths	0.58	0.64-0.81	0.04	0.1621
TotVIS6	0.87	0.82-0.92	0.03	< 0.001
TotVIS12	0.89	0.84-0.94	0.02	< 0.001
TotVIS18	0.90	0.85-0.94	0.03	< 0.001
TotVIS24	0.90	0.85-0.94	0.03	< 0.001
TotVIS36	0.90	0.85-0.95	0.03	< 0.001
TotVIS48	0.90	0.85-0.95	0.03	< 0.001
AveVIS6	0.87	0.82-0.92	0.03	< 0.001
AveVIS12	0.89	0.84-0.94	0.02	< 0.001
AveVIS18	0.90	0.85-0.94	0.03	< 0.001
AveVIS24	0.90	0.85-0.94	0.03	< 0.001
AveVIS36	0.90	0.85-0.95	0.03	< 0.001
AveVIS48	0.90	0.85-0.95	0.03	< 0.001
CumVIS	0.9	0.85-0.95	0.03	< 0.001
POPCadmit	0.56	0.49-0.62	0.04	0.0647
PCPCadmit	0.56	0.50-0.63	0.03	0.0621
PIM2	0.92	0.87-0.96	0.02	< 0.001
PIM3	0.92	0.88-0.96	0.02	< 0.001
PRISM3	0.91	0.86-0.96	0.03	< 0.001
PELOD	0.96	0.93-0.98	0.01	< 0.001
LOShours	0.72	0.64-0.81	0.04	< 0.001



RESULTS

- Total cumulative VIS had AUC of 0.90
- Sensitivity a nalysis reveals Youden's index occurs at VIS > 96.8 and reflects the optimal cut-off with sensitivity= 93.1 and specificity= 82.5
- Cumulative VIS performed similar to PIM2, PIM3, and PRISM3 in predicting poor outcome but was outperformed by PELOD

CONCLUSIONS

- Cumulative VIS can be captured in real-time using infusion pump data integrated into the electronic health record
- Based on the ROC curve, cumulative VIS > 96.8 reflects increased probability of worse outcome
- Integration of cumulative VIS into real-time a lert system could give clinicians more data for patient management and increase situational a wareness
- Multicenter evaluation is needed to evaluate if cumulative VIS maintains its superiority in predicting poor outcomes